Skip to main content
. 2020 Aug 4;17(1):39–48. doi: 10.2217/fca-2020-0029

Table 5. . FDA-approved indications for canagliflozin.

Year of label expansion Indication
2013 Adjunct to diet and exercise to improve glycemic control in adults with T2DM
2018 To reduce risk of major adverse CV events in adults with T2DM and established CV disease
2019 To reduce risk of end-stage kidney disease, worsening kidney function, CV death and hospitalization for heart failure in patients with T2DM and albuminuric kidney disease

CV: Cardiovascular; T2DM: Type 2 diabetes mellitus.